Company Overview and News

Dividend Sensei's Portfolio Update 35: If You Want To Get Rich, Follow The Data

2018-05-22 seekingalpha
There is much debate in the world of investing about how to build a portfolio to meet your long-term needs.

Why Morgan Stanley Sold MLPs during Q1 2018

2018-05-21 marketrealist
MLPs have been on a recovery path due to improvements in their financial positions, prudent capital spending, and—most importantly—recovery in earnings growth resulting from strong US production growth and strong crude oil prices.

Enbridge Simplification: A Slap In The Face To Shareholders

2018-05-18 seekingalpha
Enbridge unveils a plan to roll up all of its assets into one entity. Not wholly unexpected.

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

2018-05-15 seekingalpha
Today many people worry what the future of the job market will look like, or even whether humans will have jobs at all or be replaced entirely by automation.

Should You Invest in the InfraCap MLP ETF (AMZA)?

2018-05-10 zacks
If you're interested in broad exposure to the Energy - MLP segment of the U.S. equity market, look no further than the InfraCap MLP ETF (AMZA - Free Report) , a passively managed exchange traded fund launched on 10/14/2014.

Is Self-Funding An MLP Pipe Dream?

2018-05-09 seekingalpha
Self-funding has become a buzzword in the MLP space, but is it really translating to MLPs’ capital plans? Admittedly, the shift to self-funding is still in early innings, and the transition will take time. That said, it seems like a logical next step as the MLP space continues to mature. In today’s post, we discuss the impetus behind MLPs’ shift to self-funding and give some examples of MLPs that are pursuing self-funding.

Andeavor Logistics: High-Quality MLP Has 30-40% Upside And Trades At A 9.5% Yield

2018-05-09 seekingalpha
Andeavor Logistics sold off 11% on Monday, April 30th, on fears that it will become an "orphan" stock post the acquisition of its parent GP.

Dividend Sensei's Portfolio Update 33: A Priceless Buffett Strategy That Can Make You Rich

2018-05-08 seekingalpha
It brings to mind some of Buffett's priceless investment advice, which has made countless investors rich over the decades.

Midstream Wins, MLPs Pull Up Lame

2018-05-06 seekingalpha
It was a pretty great week for Midstream (AMEI +1.9%), but not so much for MLPs (-0.2%). The busiest week for 1Q earnings started exciting with a big merger of MLP sponsors and very strong 1Q results from big MLPs EPD and MPLX. As the week continued, however, MLP investor sentiment was dealt another blow with a surprise distribution cut from TCP and weak results from BPL.

Beating The Market, 21 Straight Hikes, Record Earnings, 7% Yield, Analyst Upgrades, 10% Distribution Growth In 2018

2018-05-05 seekingalpha
21 straight quarterly hikes, with very strong 1.27X coverage. Management is calling for 10% distribution growth in 2018.

Marathon's Historic Move Is Great For Andeavor's Investors

2018-05-03 seekingalpha
This will create the largest refiner in the US by capacity and will generate significant synergies.

Dividend Sensei's Portfolio Update 32: Is The Market Headed For A 60% Crash?

2018-05-01 seekingalpha
Investor sentiment is at its lowest point in 16 months. In fact, the majority of investors expect stocks to be lower 12 months from now.

Marathon Petroleum (MPC) Q1 Earnings Miss on Lower Margins

2018-05-01 zacks
Independent oil refiner and marketer Marathon Petroleum Corporation (MPC - Free Report) reported weaker-than-expected first-quarter results on lower fuel margin and declining income from its retail division. The company’s earnings per share came in at 8 cents, well below the Zacks Consensus Estimate of 14 cents. Specifically, refining margin of $10.58 per barrel decreased versus $11.65 a year ago.

MPLX / MPLX LP 10-Q (Quarterly Report)

Document Table of Contents

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 55336V100